The current soaring costs of Medicare and Medicaid in the USA are alarming. The government has highly suggested taking the necessary steps to solve this steady growing problem.
According to a healthcare advocate, if the government does not take healthcare seriously, it could be fatal for the economy. Americans aged 60+ will be hardest hit as they have entered the age relating to more consistent medical needs.
Melinda Gates Weighs In
Melinda Gates is the co-chair of the Bill and Melinda Gates Foundation. She is also a prominent philanthropist and author of ‘The Moment of Lift’ has weighed in. Gates says that though America has world-class healthcare facilities they are costly as well. Such sky-high prices are not favorable especially based on the country’s GDP. In her view, such costly medications can harm the economy. Furthermore, people at the age of 60+ will end up spending more money on Medicare and Medicaid.
She and husband, Bill Gates, founder of the Microsoft, are together consciously raising their voice for vaccinations. Melinda is also an expert in assisting people with the use of contraceptives for the correct family planning.
American politicians must support them with the essentials to eradicate this issue before it gets on the nerve of the country’s economy.
The Exorbitant Rates of Medicare
USA will see the GDP growth of Medicare up to 5.9% by 2038 from 3.7% in 2018. This is according to data from the SSA (Social Security Administration). If this happens, then most likely, the government will increase taxes in order to fulfill the requirements. Such expensive Medicare can devastate the whole American economy no matter how the economy performs.
In recent research, Gallup mentioned that in total, the older American population has spent $22 billion on healthcare facilities. This huge amount could have been used for other benefits.
In the end, SSA remarks that despite a substantial decrease in the average healthcare expenditure, medical facilities are still causing problems. These ideals need immediate attention. Leaving this unaddressed could result in poor side effects on the taxpayers, beneficiaries and providers.
New Opportunities For Healthcare Companies
All of these increases in cost of care equate to one thing: Opportunity. When it comes to healthcare technology, there have been few moonshot moments that have dramatically changed the face of the industry. While the healthcare juggernauts work to simply expand their reach with archaic technology, Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) has identified an open opportunity to capitalize on.
Unlike most micro-cap companies, Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) is in the prime position to take a page out of the industry’s leading corporations. What do we mean? Premier Health is hot on the trail of strategic ventures and acquisitions right now.
In addition to one of its bigger deals with Cloud Practice, Premier Health has begun working on a research pilot study with Bio Conscious Technologies (BCT) to deliver their artificial intelligence (AI) powered technology to Premier Health’s patient base.
The research pilot will use data from patients who are using the app and sign up for the study. The data used will include sugar levels, heart rate, blood pressure, age, sex and weight – much of which is collected from the integration of the patient’s health monitoring devices such as their smartwatch. The Diabits tool will then tailor a personalized blood sugar model which the patient can use to guide their nutrition and exercise plan.
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE
3 Biotech Stocks To Know in September
The biotech sector has grown at a highly impressive pace over the course of the past decade or so. It is expected that this growth is going to continue in the foreseeable future. In such a situation, it’s only prudent for investors to have a look at some of the biotech companies that are doing well. Lately the general market conditions have opened up investors’ eyes to volatility and the healthcare industry is no stranger to such conditions.
In fact, if you look at the latest trend from the Healthcare ETF XLV, for instance, you’ll see that there could be a new uptrend in the making. Due to the possibility of making significant discoveries, there is often a vast upside in numerous biotech stocks. Here is a look at three biotech stocks worth watching at this point in time.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
If you’re looking at PharmaCyte Biotech (PMCB)at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Just to give you an idea, pancreatic cancer, in general, has the highest death rate of all major cancers. Only 9% of people with this cancer will survive more than five years .
To this point, PharmaCyte Biotech (PMCB) announced that nationally and internationally renowned clinician and oncologist, Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer now that he is at Weill Cornell Medical Center.
Dr. Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, was recently appointed Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. Previously, Dr. Hidalgo was a Professor of Medicine at the Harvard Medical School and the Chief of the Division of Hematology-Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center.
Right now, PharmaCyte (PMCB) could be on the verge of a major FDA event. This industry is experiencing remarkable innovation, and now the race is to get behind the next breakthrough.
Biotech Stocks To Watch: Amgen (AMGN)
Amgen, Inc. (AMGN Stock Report) is one of the more interesting companies in the biotech industry and earlier on in 2019, the company has a phase 1 clinical trial for a cancer treatment that is supposed to combat KRAS proteins. The KRAS inhibitor medicine, known as AMG-510 has caused a lot of optimism among investors and for good reason too.
The company stated that out of the 10 non-small cell lung cancer (NSCLC) patients, 5 experienced shrinkages in their tumors. It goes without saying, that it is a significant development. There is a lot of optimism around the treatment. That’s since NSCLC is currently one of the most dangerous forms of cancer. The company presented further information about the product at the World Conference on Lung Cancer.
Biotech Stocks To Watch: Amarin (AMRN)
The other company worth considering is Amarin Corporation plc (AMRN Stock Report). The company has produced a product named Vascepa, which has been derived from fish oil and has been approved by the FDA as well. It helps in lowering triglycerides without actually raising the levels of cholesterol in the blood.
The fact that the FDA has decided to hold an AdCom meeting for Vascepa might have dampened the enthusiasm of investors. However, an analyst at Jeffries thinks the company’s long term growth is almost assured. So, this may be something to watch for now.
Biotech & Cancer Research Ignite New Interest In Healthcare Stocks
Over the past decades, cancer research has become one of the most important segments in the biotech and pharmaceutical industries. Consequently, the advances made in the field have been considerable and there are plenty of companies which have led the way with path-breaking findings.
In such a situation, it is only natural that the largest research conference in the segment is watched with a lot of keenness by those who have any interest in the industry. The event, known as ASCO, was held this past Tuesday in Chicago. There were plenty of important updates from many of the companies which attended it. Furthermore, it brought a big spotlight on biotechnology stocks in general
Why Is Cancer Research So Important?
Cancer research remains one of the most important areas of focus for most investors, simply due to the fact that if a company can come up with a truly path-breaking product then the potential return on investment could be significant.
The global market for cancer drugs is estimated to be about $123 billion and big players are investing heavily to gain an edge in this increasingly competitive market. Pharmaceutical giant Bristol-Myers, a pioneer in immunotherapy, is acquiring rival Celgene for $74 billion.
Merck is acquiring cancer drug developer Peloton Therapeutics for $1.05 billion. The announcement came as Peloton was preparing for its IPO. Earlier this year, Eli Lilly bought Loxo Oncology for $8 billion. And this is just the tip of the iceberg for cancer-fighting stocks!
New Findings Suggest GT Biopharma Therapies May Also Eliminate HIV Infected Cells
It’s a regular occurrence but one that isn’t generally covered with certain biotech companies. But with certain therapies, there can be additional applications. Most of the time they are less impactful than the target endpoints. In the case of GT Biopharma (GTBP) its Tri-Specific Killer Engager may have a massive opportunity after recent findings!
The company’s therapy showed that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could actually be eliminated!
About the HIV TriKE
In preclinical testing led by Dr. Jeffrey Miller, M.D., Deputy Director Masonic Cancer Center and Dr. Timothy Schacker, M.D., Medical School and Director, Program in HIV Medicine, the research team designed a series of Bispecific and Trispecific Natural Killer Cell Engagers (BiKE and TriKE) constructs to direct Natural Killer cell mediated cytotoxicity against an HIV infected target.
Press Release: GT Biopharma June 10th Company Update
The data demonstrate that a BiKE construct can eliminate HIV infected targets expressing the HIV envelope on their surface. Based on the success of the BiKE data, GT Biopharma is planning to develop a TriKE version by incorporating IL-15 into the BiKE scFv construct to increase the level of NK cell killing of targeted HIV infected cells.
Further Advancements Within The Industry
Amgen (AMGN) recently divulged details about its progress with regards to its product AMG 510. It is meant to be a KRAS inhibitor for tumors. According to the data, the product proved to be effective in acting against such tumors when it was used as the sole treatment and it has proven to be an encouraging update for stakeholders in the industry.
Amgen believes that their product has the potential to become a commercially successful product and it is an encouraging update, considering the fact that KRAS gene has been part of cancer treatment research for such a long time. Merck and Bristol-Myers also provided updates about their own progress with regards to their products.
Other Notable Companies
On the other hand, Merck (MRK) collaboration with AstraZeneca (AZN) has produced positive results as well. The product Lynparza showed that over a period of six months, patients who were treated with it showed a 50% reduction in the progression rate as opposed to those treated by placebo. Sanofi’s anti-CD38 drug also displayed encouraging results in Phase III of testing and it remains to be seen how the company progresses with the product in the coming months.
AstraZeneca’s study on its product Imfinzi was also displayed at the event and the three-year overall survival rate showed that it could prove to be a big break for the company. Roche, Novartis, Gilead, Nektar Therapeutics and Celgene also provided updates on their respective products.
Brad Loncar -https:// finance. yahoo. com /news/why-cancer-fighting-stocks-etfs-184606099. html
Why Arrowhead Pharmaceuticals (ARWR) Stock Doubled In 5 Months?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a pioneering company that is engaged in developing medicines for intractable ailments and over the years, it has grown into a highly influential player in the realm of RNA focussed medicines. In addition to that, the market has also recognized the true scope of the medicines that the company makes and its stock has appreciated considerably over the past year or so.
In 2018 alone, the Arrowhead stock rose by as much as .35% and from early January this year until date, the stock has gained another 100%. The reason behind Arrowhead’s rise is due to ARO-HBV, a product that is supposed to be a cure for people afflicted with the Hepatitis B virus.
However, there have been many more important developments that make Arrowhead such a compelling company. In addition to being the most important driver for the stock, ARO-HBV is also being recognized by big-ticket corporations now.
In a landmark development, healthcare behemoth Johnson and Johnson paid the company $250 million for the purpose of licensing the product. It has been renamed JNJ-3989 and Arrowhead stands to gain as much as $1.6 billion in milestone payments as well, in addition to royalty percentages.
The prospect of the JNJ-3899 product is immense and with Johnson and Johnson as the vendors, it has the possibility of becoming one of the most successful medicines. The Hepatitis B virus is extremely damaging and according to reliable data, around 900000 people die from the virus every year. Hence, there is a possibility of JNJ-3899 becoming a global leader in this particular segment.
However, for Arrowhead, ABO-HBV is not the only product that it has developed and it has already started working on other products. It has also emerged that the company has gone into a partnership with drug maker Amgen and are working on three new products that are going to go into clinical trials soon. Considering the company’s track record, these factors could take the stock to new heights.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Biotechnology2 weeks ago
This Biotech Stock Could Hold the Key to a Multi-Billion Dollar Market Shake-up
Featured6 days ago
Tiziana Life Sciences (TLSA) Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
Biotechnology2 weeks ago
Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key
Featured2 weeks ago
This Biotech Stock is Looking to Deliver Huge Positive Change
Featured6 days ago
Top 4 Penny Stocks To Watch This Week
Biotechnology2 weeks ago
Are Biotech Stocks Setting The Stage For Another Bull Trend?
Biotechnology2 weeks ago
Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers
Featured5 days ago
Airline Stocks In Focus; Spur Interest In Detection Tech Companies?